Calithera Biosciences, Inc.
Calithera Biosciences operates under a plan of liquidation approved in January 2023. The company previously focused on clinical stage precision oncology biopharmaceuticals. Founded in 2010, its headquartered in South San Francisco, California.
Overview
Strengths
- Valued below its Financial Services peers: P/B 0.0x vs. a median of 1.4x.
- Cheaper than its own history: P/B 0.0x vs. a historical average of 5.1x.
Weaknesses
- Our discounted cash flow model finds no value to support the current price: projected cash flows do not cover its debt and current valuation.
- Shareholder dilution: the share count has grown by 15.3% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Low profitability: return on equity of 0.0%, below the 8% that typically covers a financial company's cost of equity.
- Small company (enterprise value $487): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data